The agreement – which has been valued at up to $1.15 billion – is the strongest signal yet of Hims & Hers' aspirations to grow into a global health player, with the addition of Eucalyptus giving it a ...

The 7th Dermatology Drug Development Summit Europe is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists shaping the ...

The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new medicines on two pivotal trials, according to Commissioner Marty Makary.

The new NICE guidance recommends that most people should now be offered metformin along with an SGLT-2 inhibitor from the start, while also advising that they get a slow-release formulation of ...

The agreement gives MSD (known as Merck & Co in the US and Canada) access to the Mayo Clinic Platform architecture – which covers de-identified laboratory results, medical imaging, clinical notes, ...

Traditional virtual engagement often forces patients into a corporate mould – a 60-minute, high-pressure web meeting where the loudest voice dominates and key insights are lost to language or time ...

The long months without stable leadership at the CDC in the US look set to continue, as the Trump administration confirms that NIH Director Jay Bhattacharya will step in as acting director of the ...

The three-year study – led by mental health data science company Akrivia Health in partnership with Cardiff University – will ...

Managing bipolar I disorder (BD-I) is a long-term commitment, and factors such as symptoms and side effects influence ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

Following his return from San Francisco and the JP Morgan Healthcare conference last month, editor-in-chief Jonah Comstock ...

The analysis by property advisory firm Knight Frank found a 22% increase in the number of life sciences companies domiciled in the UK between 2019 and the end of 2025, to a total of 15,436.